Telomir Pharmaceuticals, Inc.(TELO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
TELO Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Telomir Pharmaceuticals, Inc. (TELO), a Healthcare sector company. TELO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Telomir Pharmaceuticals, Inc. reports net income of $-990.9K, free cash flow of $-1.8M. Top institutional holders of TELO by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. TELO trades on the Nasdaq exchange and files with the SEC under CIK 1971532. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TELO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Telomir Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-990.9K
Free Cash Flow
Q1 2026
$-1.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+20.3% YoYEPS (Diluted)
-168.8% YoYTotal Assets
+53.8% YoYOp. Cash Flow
+4.4% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Net Income | $-10.4M +20.3% | $-13.1M -1430.4% | $-854.1K | — |
| EPS (Diluted) | $-0.33 -168.8% | $0.48 +1700.0% | $-0.03 | — |
| Total Assets | $7.3M +53.8% | $4.8M +9696.4% | $48.7K | — |
| Operating Cash Flow | $-3.7M +4.4% | $-3.9M -723.6% | $-468.7K | — |
AI Insight: TELO Ratio Trends
Telomir remains unprofitable with ROE deteriorating to -79.9% in Q1 2026, though ROA improved sequentially from -68.5%.
• ROE worsened sharply to -139.4% in Q4 2025, then improved to -79.9% in Q1 2026—still deeply negative.
• ROA improved from -59.6% in Q3 2025 to -68.5% in Q4 2025, then -68.5% in Q1 2026—persistent operational losses.
⚠ TTM ROE of -185.9% signals cumulative 12-month losses; company has no profitable quarters in dataset.
⚠ No operating margin, NPM, or ROIC data available; cannot assess cash generation or operational efficiency trends.
Get alerted when TELO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Telomir Pharmaceuticals, Inc. including:
Top Institutional Holders of TELO
VANGUARD CAPITAL MANAGEMENT LLC
$1.3M995,373 shBlackRock, Inc.
$376.0K289,198 shGEODE CAPITAL MANAGEMENT, LLC
$324.0K249,086 shVANGUARD FIDUCIARY TRUST CO
$176.2K135,541 shMILLENNIUM MANAGEMENT LLC
$167.8K129,060 shSTATE STREET CORP
$76.2K58,600 shBank of New York Mellon Corp
$66.9K51,454 shSuncoast Equity Management
$66.6K51,194 shNORTHERN TRUST CORP
$54.4K41,844 shWorld Investment Advisors
$48.1K37,037 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.3M | 995,373 |
| BlackRock, Inc. | $376.0K | 289,198 |
| GEODE CAPITAL MANAGEMENT, LLC | $324.0K | 249,086 |
| VANGUARD FIDUCIARY TRUST CO | $176.2K | 135,541 |
| MILLENNIUM MANAGEMENT LLC | $167.8K | 129,060 |
| STATE STREET CORP | $76.2K | 58,600 |
| Bank of New York Mellon Corp | $66.9K | 51,454 |
| Suncoast Equity Management | $66.6K | 51,194 |
| NORTHERN TRUST CORP | $54.4K | 41,844 |
| World Investment Advisors | $48.1K | 37,037 |
More Healthcare Companies
View all Healthcare →Put TELO on your watchlist
Track score changes the day Telomir Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TELO a good stock to buy?
13F Pro's AI-powered analysis of Telomir Pharmaceuticals, Inc. (TELO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TELO are available on the TELO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TELO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TELO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Telomir Pharmaceuticals, Inc.'s investment landscape.